Lupin launches nasal spray in the United States

Lupin Limited has announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), in 0.03% and 0.06% strengths, in the United States. The solutions are bioequivalent to Boehringer Ingelheim's Atrovent Nasal Spray. The 0.03% solution is indicated for rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged six years and older, while the 0.06% solution addresses rhinorrhea from common colds or seasonal allergies in adults and children five years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of USD 63 million in the U.S. as of May 2025.